Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction: Dichotomous response as a function of age in the GUSTO V trial
European Heart Journal, ISSN: 0195-668X, Vol: 24, Issue: 20, Page: 1807-1814
2003
- 54Citations
- 24Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations54
- Citation Indexes53
- 53
- CrossRef23
- Clinical Citations1
- PubMed Guidelines1
- Captures24
- Readers24
- 24
Article Description
Background: Intracranial haemorrhage is an important limitation to pharmacologic reperfusion therapy for acute myocardial infarction. The combination of a glycoprotein IIb/IIIa inhibitor, half-dose plasminogen activator and reduced-dose heparin has been evaluated as an alternative to standard fibrinolytic therapy in this setting. Methods and results: We evaluated the relation between univariate and multivariate predictors of intracranial haemorrhage and the effect of treatment with either reteplase alone (10 U bolus twice, 30 min apart) with standard-dose heparin (5000 U bolus followed by an infusion of 1000 U h for patients ≥80 kg and 800 U h for those <80 kg) or combination therapy with abciximab (0.25 mg/kg bolus and 0.125 μg/kg/min for 12 h) and half-dose reteplase (two boluses of 5 U 30 min apart) with reduced-dose heparin (60 U kg bolus, maximum 5000 U, followed by an infusion of 7 U kg h ) in the 16 588 patients randomized in the GUSTO V trial. Overall, the incidence of intracranial haemorrhage was similar in the two groups (0.6% vs 0.6%; OR 1.05, 95% CI 0.71, 1.56). The median (25th-75th) time from drug administration to intracranial haemorrhage was 5.5 (3.4-11) hours with combination therapy and 9.2 (5.9-22) hours with reteplase (P=0.048). Among the multivariable predictors of intracranial haemorrhage, only age showed a significant interaction with treatment effect (age per treatment interaction chi-square 4.60, P=0.032) with a lower risk of combination therapy for younger patients and a higher risk for the elderly. Conclusions: Although no additional risk of intracranial haemorrhage has been observed with combination therapy in the whole population, a significant age per treatment interaction exists, with a lower risk with combination therapy in younger patients, and a higher risk in the elderly. © 2003 Published by Elsevier Ltd on behalf of The European Society of Cardiology.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0142104875&origin=inward; http://dx.doi.org/10.1016/j.ehj.2003.07.004; http://www.ncbi.nlm.nih.gov/pubmed/14563339; https://academic.oup.com/eurheartj/article-lookup/doi/10.1016/j.ehj.2003.07.004; https://dx.doi.org/10.1016/j.ehj.2003.07.004; https://academic.oup.com/eurheartj/article/24/20/1807/559149
Oxford University Press (OUP)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know